Metalyse

Tenecteplase, the active ingredient in Metalyse, is a thrombolytic agent presented as a powder for solution for injection for intravenous use. It facilitates rapid clot dissolution in the coronary arteries of adults experiencing an acute ST‑segment elevation myocardial infarction (STEMI), helping to restore blood flow and limit heart muscle damage. The drug is supplied in a sterile lyophilized form that is reconstituted immediately before administration under aseptic conditions.

GNH USA supplies Metalyse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metalyse (tenecteplase) is a thrombolytic agent used in the management of acute coronary artery occlusion.

Acute myocardial infarction (STEMI): rapid reperfusion to restore coronary blood flow and limit myocardial injury.

Common Side Effects: - Bleeding at the injection site: mild to moderate bruising or hematoma. - Nausea: transient gastrointestinal discomfort. - Headache: mild to moderate intensity. - Hypotension: temporary drop in blood pressure. - Fever: low‑grade temperature elevation. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Intracranial hemorrhage: potentially life‑threatening bleeding in the brain. - Severe allergic reaction: anaphylaxis or angioedema. - Myocardial rupture: rare tearing of heart muscle. - Disseminated intravascular coagulation: abnormal clotting throughout the body. - Severe hypotension: profound drop in blood pressure requiring intervention. - Pulmonary hemorrhage: bleeding within the lungs.

Metalyse should be used only after careful assessment of bleeding risk and contraindications.

Assess bleeding risk: evaluate recent surgery, trauma, or active hemorrhage. Avoid in active internal bleeding: contraindicated when uncontrolled bleeding is present. Use with caution in uncontrolled hypertension: high blood pressure increases hemorrhagic risk. Monitor coagulation parameters during therapy: track PT/INR and aPTT as needed. Contraindicated in known hypersensitivity to tenecteplase or its excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tenalyse may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other thrombolytic agents: additive risk of severe bleeding. - Therapeutic anticoagulants (heparin, low‑molecular‑weight heparin, warfarin): increased anticoagulant effect. - Full‑dose antiplatelet drugs (e.g., clopidogrel, aspirin): heightened bleeding tendency.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may amplify bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): potential platelet dysfunction. - Glycoprotein IIb/IIIa inhibitors: monitor for excessive bleeding.